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ABSTRACT  
 
Background 
Even though there have been marked increases in the number of patients accessing HIV care 
and treatment in sub-Saharan Africa, challenges in patient retention remain.  Most health 
systems in sub-Saharan Africa routinely report on loss to follow up of patients, but only a 
limited number of factors associated with loss to follow up are measured. In Kenya there is 
limited research on loss to follow up in HIV care and treatment programs. This study reports 
on rates of loss to follow up and factors associated with loss to follow up at the New Nyanza 
Provincial General Hospital (NNPGH) in Kisumu, Kenya. 
 
Methods 
A retrospective cohort study of 4,740 adult patients that was registered for HIV and AIDS 
care and treatment between 2003 and 2008 was conducted. Data was analysed using SAS 9.2 
and STATA 10. Cox proportional hazard ratio was calculated to describe the association 
between risk factors and loss to follow up. 
 
Results 
Of the total 4740 patients, 64.6% were female, males [median age of 36 (IQR 30-44) years 
vs. 32 (IQR 26-39) years for females] were older than females, more males (68.3%) were 
married, more females (6.2%) had no education and 68% of all patients enrolled had been 
lost to follow up over 6 years. Risk for lost to follow up was greater amongst males (Adjusted 
Hazard Ratio (AHR) =1.12; 95% Confidence Interval (CI) = 1.02-1.22); younger patients 
(15-30 vs. >40 years: AHR=1.37, 95%CI = 1.23 – 1.53; and 31-40 vs. >40 years: AHR=1.15, 
95%CI=1.03-1.28); those who were unemployed (AHR=1.14, 95%CI=1.05-1.25); and having 
advanced HIV disease (WHO stage 4 vs. WHO stage 1: AHR=1.53, 95%CI=1.29-1.81). 
Patients on ART (AHR=0.64, 95%CI=0.52-0.78) at enrollment were less likely to be lost to 
follow-up compared to those in HIV care.  
 
Conclusion 
More attention is needed in developing retention strategies for patients with much focus on 
patients on care. Targeted intervention is required to improve retention amongst males, 
unemployed patients, patients with advanced HIV disease and younger patients. Additionally, 
targeted follow up in the community for Patients on care is required.  
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Definition of terms 
 
Loss to follow up - Patient who has missed clinic visit for a period more than 3 months (90 
days) (Ministry of Health, 2007) and there are no records indicating that the patient has been 
transferred to other clinic or dead. 
 
Retention – ability of a program to follow up patients in care and treatment with minimal 
dropout or loss to follow-up rates. 
 
Care – provision of Cotrimoxazole and other supportive services to HIV infected patients to 
assist in preventing preventable illnesses. 
 
ART – Provision a package of services that includes but not limited to antiretroviral drugs 
and care and support services 
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1.1 Background 
Since the identification of Human Immunodeficiency Virus and Acquired Immunodeficiency 
Syndrome (HIV/AIDS) in 1981 (WHO, 2003b), this pandemic has continued to rob countries 
of the resources and capacities for human security and development (UNAIDS and WHO, 
2002). The HIV/AIDS pandemic has continued to be a heavy public health Achilles heel and  
more so in sub-Saharan Africa (UNAIDS, 2004; UNAIDS, 2008; UNAIDS and WHO, 2001; 
UNAIDS and WHO, 2002; UNAIDS and WHO, 2006; UNAIDS and WHO, 2009; WHO, 
2008). In 2010, an estimated 34 million people were living with HIV/AIDS including 3.4 
million children under the age of 15 years. It is further estimated that there were 2.7 million 
incident infections and that approximately 1.8 million people died of HIV related illnesses 
(WHO, UNAIDS and UNICEF, 2010). 
 
Sub-Saharan Africa which contributes to only 10% of world’s population, disproportionately 
contributes to an estimated 23.1 million (68%) of the total worldwide population of People 
living with Human Immuno-deficiency Virus (PLHIV) in 2010 (WHO, UNAIDS and 
UNICEF, 2010). Additionally, 59% of PLHIV in Sub-Saharan Africa were women (WHO, 
UNAIDS and UNICEF, 2010). The region also accounted for 70% of all new HIV infections 
among adults. In addition, 67% of all deaths due to HIV/AIDS in the world occurred in sub-
Saharan Africa. HIV/AIDS has impacted negatively on communities due to loss of 
productivity from mortality and morbidity in 30 to 50 years age group. It is projected that an 
additional 6 million households will be in poverty by 2015 due to either  loss of productivity 
or the burden of disease in this age group unless national responses such as increased access 
to Antiretroviral Therapy (ART) and support to PLHIV are strengthened (UNAIDS, 2008). 
 
HIV/AIDS in Kenya 
The Kenya AIDS Indicator Survey (KAIS) of 2007 conducted by the National AIDS and STI 
program estimated the national adult (15 – 64 years) HIV prevalence at 7.1% with an 
estimated 1.4 million PLHIV (National AIDS and STI Control Program and Kenya Ministry 
of Health, 2009). The report further estimated that the HIV prevalence among adults in the 15 
to 49 years age group to be 7.4% (National AIDS and STI Control Program and Kenya 
Ministry of Health, 2009). The HIV prevalence in the 15-49 years age group  was not very 
different from those reported in the Kenya Demographic and Health Survey (KDHS) of 2003 
(Central Bureau of Statistics, Ministry of Health Kenya and ORC Macro, 2003). KAIS also 
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estimated that of the 1.4 million PLHIV, 138,000 (9.7%) were on antiretroviral therapy 
(ART) at the time of the survey in 2007. The report further indicates that the HIV prevalence 
is higher in the urban areas (8.4%) compared to rural areas (6.7%) (National AIDS and STI 
Control Program and Kenya Ministry of Health, 2009). 
 
Nyanza province has the highest HIV prevalence at 14.9% compared to the other seven 
provinces in Kenya. HIV prevalence in Nyanza is double the national prevalence and is home 
to an estimated 417,000 PLHIV (National AIDS and STI Control Program and Kenya 
Ministry of Health, 2009). In Nyanza, of the 56,000 patients that are eligible for ART, 44,000 
are on ART (National AIDS and STI Control Program and Kenya Ministry of Health, 2009). 
The HIV prevalence in the rural areas at 14.9% in the province is slightly higher than the 
prevalence in the urban areas at 13.9% which is reverse of the national trend (National AIDS 
and STI Control Program and Kenya Ministry of Health, 2009). 
 
Impact of support towards HIV program on mortality and morbidity  
Since the introduction of ART in 1996, there has been substantial reduction in mortality and 
morbidity (Montaner et al., 1998). In countries with adequate resources, ART has greatly 
improved the outcome of treatment  such as quality of life for patients with HIV/AIDS 
(Egger et al., 2002; Schneider et al., 2005; Walensky et al., 2006). Additionally, use of 
Cotrimoxazole Preventive Therapy (CPT) in sub-Saharan has also been shown to prolong life 
(Mwaungulu et al., 2004; Nunn et al., 2008) resulting in improved outcomes for patients 
started on CPT (Nunn et al., 2008) including those in successfully integrated TB and HIV 
services (Friedland, Harries and Coetzee, 2007). 
Due to the heavy burden and negative impact of HIV/AIDS and more so to sub-Saharan 
Africa, joint efforts and resources have been mobilized globally and geared towards 
ameliorating the effects to these populations. Joint efforts such as the “3 by 5’” initiative in 
2003 which aimed at improving access to ART to 3 million people by the year 2005 (WHO, 
2003c) whose target was later achieved in the year 2007 (WHO, 2009). In addition to 
political commitment (WHO, 2009), other substantial effort and support by multiple partners 
has led to expansion of HIV/AIDS HIV care and treatment programs (WHO, 2009).  These 
efforts have resulted in expanded access to HIV care and treatment services evidenced by 
improved ART coverage and access with an estimated 4,030,000 in 2008 up from only 
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400,000 in 2003 worldwide; 2,925,000 in 2008 up from only 100,000 in 2003 in sub-Saharan 
Africa and an increase from 177,000 in 2007 to 242,881 in 2008 in Kenya. This improvement 
has resulted in an overall coverage of 31% globally and 30% in sub-Saharan Africa 
(UNAIDS and WHO, 2009). Despite the success in Sub-Sahara Africa, there are still gaps 
such as shortage of human resources that need to be addressed (Muula et al., 2007), 
sufficiently trained health care personnel, inadequate facilities, complexity of drug regimens 
and formulations and compartmentalization of ART program that have negative impact on 
referral and linkages (Meyers et al., 2007). 
 
Influence of retention on patient treatment outcomes 
 Long term retention is important in achieving adherence in treatment HIV care and treatment 
programs even though most HIV care and treatment programs have paid less attention to 
patients lost due to attrition (Rosen, Fox and Gill, 2007). Initiation of care (opportunistic 
infections preventive care) and ART to HIV infected persons reduces morbidity and mortality 
hence the need for patient to continue with care and treatment without dropping out (National 
AIDS and STI Control Program and Kenya Ministry of Health, 2007; National AIDS and STI 
Control Program and Kenya Ministry of Health, 2008). Optimal adherence to ART (taking 
95% or more of medication) is important in preventing treatment failure and development of 
drug resistance (National AIDS and STI Control Program and Kenya Ministry of Health, 
2007).  Non-adherence to treatment results in severe consequences such as poor clinical 
outcomes (WHO, 2003a), worsening of the condition being treated, death and increased 
health care costs, deaths, and hospitalizations (Frost and Sullivan, 2010; Osterberg and 
Blaschke, 2005). Additionally, poor adherence can lead to development of viral resistance 
and treatment failure amongst HIV infected patients on ART posing a great public health 
problem (WHO, 2003a).   
 
1.2 Problem statement 
New Nyanza Provincial General Hospital (NNPGH) HIV Comprehensive Care Clinic (CCC) 
has been providing care and ART to PLHIV since 2003. As of December 2011 an estimated 
21,000 HIV infected adults and children had ever been enrolled for care and ART at the 
CCC. However, an estimated 15-20% of patients initially enrolled for HIV care and ART, are 
no longer receiving care at the clinic (Omollo, 2009). There is however limited information 
on the actual proportion of patients lost to follow-up and the associated factors thus the need 
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to determine the rates and factors associated with loss to follow-up among adult HIV-infected 
patients enrolled at the CCC between 2003 and 2008. Determination of rates of loss to 
follow-up and factors associated to loss to follow up may provide insight for future 
interventions and resources needed to maximize retention.  
 
1.3 Study aim and objectives 
The aim of this study was to describe and compare loss to follow-up between the patients on 
care and those on Cotrimoxazole Preventive Therapy (CPT) and ART; and to determine the 
factors associated with loss to follow up among adult HIV- patients enrolled in New Nyanza 
Provincial General Hospital HIV Comprehensive Care Clinic between January 2003 and 
December 2008. 
The objectives were: 
 To describe the demographic and clinical characteristics of HIV infected adults enrolled 
for HIV/AIDS care and treatment. 
 To calculate loss to follow-up of HIV infected adults. 
 To determine factors associated with loss to follow up among HIV infected adults. 
 To compare the rates of loss to follow up and associated factors between HIV/AIDS care 
and ART groups. 
 
1.4 Study setting  
This study was set within the NNPGH CCC 2003 – 2008 evaluation which has approval from 
Kenya Medical Research Institute (KEMRI) Ethical Review Committee (ERC). NNPGH is 
the regional referral hospital for Nyanza province with a  population of 5.4 million in 2009 
(Kenya National Bureau of Statistics, 2010). NNPGH mainly serves the population in Nyanza 
province though patients from neighbouring provinces (Rift Valley and Western province) 
may also be referred to the hospital for specialised treatment. It offers a variety of services 
including out-patient care with general and special cases clinics such as Medical, Paediatric, 
Surgical, Obstetrics and Gynaecology out-patient clinics, both in-patient and out-patient 
pharmacies, in-patient care with a capacity of 442 beds, CCC and a laboratory with capability 
to offer several tests including specialised tests such as CD4 cell count for PLHIV as 
recommended by Ministry of health (MoH) (Ministry of Health, 2006). 
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In NNPGH, HIV specific programmatic efforts began in May 2001, with the introduction of 
Prevention of Mother to Child Transmission (PMTCT-Plus) Programme which aimed at 
reducing the transmission of HIV from the mother to the child (Ministry of Health, 2006). 
The CCC was started in January 2003 and provides both HIV care and ART to patients. The 
patients on care benefit from CPT, psychosocial support, nutritional supplementation, 
laboratory monitoring and treatment and prevention of other opportunistic infections (OI). 
Additionally, patients who are eligible for ART are initiated on ART as per the Ministry of 
Health guidelines (National AIDS and STI Control Program and Kenya Ministry of Health, 
2007). As part of these guidelines, patients are required to enroll into the CCC and are then 
provided with CPT, Multivitamin, regular monthly or quarterly follow-up, supportive 
counselling, baseline laboratory testing, including but not limited to CD4 count testing, 
Complete Blood Count (CBC) and Liver Function Tests (LFTs), assessment and possible 
initiation of ART accompanied by monthly clinical and six-monthly laboratory monitoring or 
as deemed necessary by the clinician.  
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2. Literature review 
“Loss to follow-up” has been defined by several authors as patients missing two or more 
consecutive clinic appointments (Wester et al., 2005) or when a patient had not been seen at 
the clinic for at least 2 or 3 months (Calmy et al., 2006; Wools-Kalaustian et al., 2006; 
Laurent et al., 2005). In Kenya, the National AIDS and STI which co-ordinates all HIV care 
and treatment programs considers a patient as “loss to follow up” when the patient had 
missed their scheduled appointment for a period of more than three months (Ministry of 
Health, 2007). 
Globally, it is estimated that more than 20% of patients on ART are not retained in ART 
programmes after 12 months and retention is even worse with less than three quarters 
retained at 4 years (WHO, 2009). On the other hand, in sub-Saharan Africa, of the total 
74,289 patients included in the analysis, 22.5% (16,715) had dropped from care and 
treatment. Amongst those that dropped from care and treatment, 56% (9,360) were due to 
loss to follow up (Rosen, Fox and Gill, 2007).  Additionally, in sub-Saharan Africa retention 
on ART HIV care and treatment programs is estimated to be 75% at 12 months and 67% at 
24 months of treatment and stabilizes afterwards (WHO, 2009). However, several HIV care 
and treatment programs recorded high retention rates between 67% and 84% (Barth et al., 
2008; Bekker et al., 2006; Dalal et al., 2008; Lawn et al., 2006; Makombe et al., 2008; Orrell 
et al., 2007; Severe et al., 2005). In a recent systematic review of retention in Sub-Saharan 
Africa, Rosen and Fox assessed retention at various stages from testing to treatment 
initiation. The pre-ART retention rate was lowest at 46% in a Cape Town township public 
clinic in South Africa and highest at 70% in Arba Minch hospital in Ethiopia (Rosen and Fox, 
2011). 
Mortality among patients on ART and those on not on ART were comparable. Mortality 
amongst patients on ART were from proportions as low as 6.6% to as high as 19% while that 
among patients not on ART were estimated at between 5% and 19% (Barth et al., 2008; 
Bekker et al., 2006; Karcher et al., 2007; Laurent et al., 2005; Lawn et al., 2006; Makombe 
et al., 2008; Orrell et al., 2007; Severe et al., 2005; Sow et al., 2007; Wools-Kalaustian et al., 
2006).  
 
Loss to follow up is contributed to by reasons such as complex therapeutic regimen 
(Osterberg and Blaschke, 2005), loss of hope in medication, belief in spiritual healing, 
excessive alcohol consumption, being bed ridden, lack of disclosure, no money for transport 
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and some transfer out without informing the clinic (Deribe et al., 2008). Loss to follow up 
among patients on ART has been estimated by several studies and HIV care and treatment 
programs to be between 3% and 29% with the highest being in Kibera Kenya (Barth et al., 
2008; Bekker et al., 2006; Dalal et al., 2008; Karcher et al., 2007; Laurent et al., 2005; Lawn 
et al., 2006; Makombe et al., 2008; Orrell et al., 2007; Severe et al., 2005; Sow et al., 2007; 
Unge et al., 2009; Wools-Kalaustian et al., 2006; Yu et al., 2007). 
 
2.1 Characteristics of patients at enrollment 
Patients in majority of the studies and HIV care and treatment programs had a median age 
less or equal to 35 years at enrolment with 45% of them being in the 30-39 years age group 
(Barth et al., 2008; Lawn et al., 2006; Lawn et al., 2005; Stringer et al., 2006; Brinkhoft et 
al., 2008). In contrast, HIV care and treatment programs in Kenya and Uganda had older 
patients with a median age of more than 35 years (Kamya et al., 2007; Marston et al., 2007; 
Wools-Kalaustian et al., 2006). 
Females were dominant in most HIV care and treatment programs and comprised from as low 
as 46% to 74% of patients of enrolled patients  (Amuron et al., 2009; Brinkhoft et al., 2008; 
Kamya et al., 2007; Lawn et al., 2006; Lawn et al., 2005; Marston et al., 2007; Orrell et al., 
2007; Stringer et al., 2006; Wools-Kalaustian et al., 2006). In contrast, a clinical cohort in 
France and an ART program in the Malawi police force had more men comprising 78% and 
75% respectively (Lebouche et al., 2006; Makombe et al., 2008). 
An estimated 51% in a cohort of patients in South Africa at enrolment had no education 
(Barth et al., 2008) compared to an ART program in western Kenya and Haiti which had only 
8% and 17% of patients enrolled with no education respectively (Severe et al., 2005; Wools-
Kalaustian et al., 2006). In Kenya, of the proportion that attended school, the median years of 
school attendance was 9 (Wools-Kalaustian et al., 2006). 
Patients in most HIV care and treatment programs had a median CD4 cell count less than 250 
cells/l3 (Barth et al., 2008; Kamya et al., 2007; Lawn et al., 2006; Lawn et al., 2005; Orrell 
et al., 2007; Wools-Kalaustian et al., 2006; Brinkhoft et al., 2008; Marston et al., 2007; 
Stringer et al., 2006). Most patients initiating ART in sub-Saharan Africa were enrolled with 
advanced clinical disease with most HIV care and treatment programs having more than 70% 
of patients in WHO stage 3 and 4 (Barth et al., 2008; Kamya et al., 2007; Lawn et al., 2006; 
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Lawn et al., 2005; Makombe et al., 2008; Marston et al., 2007; Stringer et al., 2006). Other 
HIV care and treatment programs however still registered proportion of patients in WHO 
stage III and IV lower than 70% (Amuron et al., 2009; Brinkhoft et al., 2008; Wools-
Kalaustian et al., 2006). In Guguletu, South Africa, Bekker and others showed changes in 
WHO clinical staging trends and that there was a decrease in the proportion of patients 
enrolled in stage IV over the years from 44% in 2002/3, 25% in 2003/4 and 21% in 2004/5 
(Bekker et al., 2006). 
Only 23.9% of patients enrolled in a South Africa program were employed (Barth et al., 
2008) compared to 30.5% of patients having employment outside home in western Kenya 
(Wools-Kalaustian et al., 2006). Of patients enrolled, 49.2% were living with a partner in 
South Africa (Barth et al., 2008) compared to 64% who were married in western Kenya 
(Wools-Kalaustian et al., 2006). 
2.2 Factors contributing to loss to follow up 
2.2.1 Period of patient’s time on care and treatment 
ART is a lifelong treatment and patients once initiated on it will continue on treatment. 
Period of treatment has been shown to influence patient outcomes. In an urban clinic in 
Cameroon, ART eligible patients who were older than 14 years were initiated on ART and 
prospectively followed for a period of 18 months. Findings from this study showed that 
patients were most likely to be lost to follow during the first 6 months of ART initiation 
(Tsague et al., 2009). Additionally, Patients lost to follow up at 12 months had significantly 
high CD4 cell count compared to those retained in the program. Those patients with CD4 cell 
counts above 50 cells/l3 and without Tuberculosis (TB) infection were more likely to remain 
in care (Tsague et al., 2009).  
In a study at a Hospital in Yaounde Central Hospital in Cameroon where 312 patients 
initiated on ART were followed up for 6 months, results showed that most losses to follow up 
occurred during the initial months of ART initiation (Rougemont et al., 2009). In a study by 
Wools Kalaustian et al. (2006), it was demonstrated that the risk of a patient being lost to 
follow up was associated with the length of time on treatment. The study also indicated that 
losses to follow up after two and three years of treatment were 24.5% and 29.7% 
respectively. 
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2.2.2 Age of the patient 
In a review of ART programmes in 13 low income countries in Northern Africa, Southern 
Africa, Eastern Africa, Central and Western Africa, South America and Asia, data for 5,491 
patients were reviewed and included in the analysis.  Results indicated that patients who were 
old were more likely not to return to the clinic after the first visit (Brinkhoft et al., 2008). In 
contrast, a study looking at 253 patients from hospitals in Malawi, results indicated that the 
patients who had defaulted were at a much young age of 35 years (Yu et al., 2007).  
Similar findings to those in the Malawi study by Yu et al. were noted in an urban clinic in 
France where a cohort of 1,756 patients was followed up for about 13 years. Results indicated 
that the younger the patients were, the more likely they were to be lost to follow up and that 
patients who were younger than 30  years of age (52%) were more likely to be lost to follow 
up followed by those who were 30-40 years old (37%) and lastly by those who were older 
than 40 years of age (11%) (Lebouche et al., 2006). Similar results were documented in a 
study in Migori Kenya which followed up PMTCT patients together with their partners and 
children enrolled in the HIV clinic for a period of about 20 months. Results indicated that 
young age was associated with more clinic drop outs (Karcher et al., 2007). 
2.2.3 Gender of the patient 
In a Uganda study looking at loss to follow up of patients screened for ART eligibility before 
ART initiation, males were more likely not to complete the three required pre-ART screening 
visits compared to females (Amuron et al., 2009). Similar findings in a large ART program in 
western Kenya where data of 2,059 patients were reviewed indicated that males were 
significantly more likely to be lost to follow up compared to  females (Wools-Kalaustian et 
al., 2006).  Males were also associated with early mortality and reduced chances of survival 
which may have contributed to early loss to follow up (Lawn et al., 2006; Nachega et al., 
2006).  
Of contrast are the results of a study comparing outcomes of patients in a central hospital 
compared to those in three peripheral hospitals in Malawi. Results showed that 60% of 
patients lost to follow up were females (Yu et al., 2007). In an urban clinic cohort in France 
which had more males (78%) than females, the proportion of  loss to follow up between 
males and females were not significantly different (Lebouche et al., 2006). 
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2.2.4 Economic status of the patient 
Patient’s economic status was associated with probability of loss to follow up as 
demonstrated in Kibera Kenya and France. In Kibera which is largely an informal settlement, 
an ART program based in Kibera provided services to both Kibera and non-Kibera residents. 
Results from Kibera showed that patients who were Kibera residents and lived under hard 
conditions were 11 times more likely to drop out from treatment programmes compared to 
non-Kibera residents (Unge et al., 2009). In an urban clinic in France, unemployment was 
associated with loss to follow up of patients (Lebouche et al., 2006). In contrast, Rougemont 
and others (2009) in a study in Yaunde Central Hospital in Cameroon found that income was 
not associated with adherence.  
In an ethnographic study done in both Tanzania and Nigeria by Ware and others, participants 
indicated that most adherence obstacles were due to resource constraints. The participants in 
the study indicated that obtaining money for transportation to clinic appointments was a 
challenge. Most patients had to borrow or “beg” for money to raise money for transportation 
to the clinic (Ware et al., 2009) 
2.2.5 Clinical status of the patient 
Clinical status of the patients has also been shown to influence patient outcomes and loss to 
follow up. Yiannoustos and others in review of a HIV treatment program in western Kenya 
with 8,977 enrolled patients showed that patients with advanced WHO stage (stage 3 or 4) 
were more likely to be lost to follow up compared to those in stage 1 or 2 (Yiannoutsos et al., 
2008).   Similar results were found in a study in a hospital in Yaounde Cameroon. A cohort of 
patients starting ART was followed up for a period of 6 months to determine outcomes. 
Patients who had CDC stage B and C disease were more likely to be lost to follow up 
compared to those who were asymptomatic and CDC stage A (Rougemont et al., 2009).  
Stringer and others in their study in Zambia showed that patients in WHO stage 4 were more 
likely not to adhere to ART in the first 6 months of therapy and in effect impacting negatively 
on CD4 and outcome (Stringer et al., 2006). In a Malawi study comparing outcomes of 
patients enrolled in a central hospital compared to those in three peripheral hospitals, patients 
in WHO stage 3 and 4 contributed to 91% and 99% of patients lost to follow in the central 
hospital and three rural hospitals respectively (Yu et al., 2007) 
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Contrasting results were documented in a review of HIV treatment programs across selected 
15 countries across Africa, Asia and South America by Brinkoft et al. and Lawn et al. where 
records of 5,419 patients who had been followed up for more than 12 months were analyzed. 
Advanced clinical disease of patient was not associated with loss to follow up (Brinkhoft et 
al., 2008). Similar results were also indicated by Lawn and others in a study looking at 
determinants of mortality and non-death losses from an ART service in South Africa (Lawn 
et al., 2006).  
2.2.6 Immunological status of the patient 
Immunological status of the patients has been shown to influence patient outcomes. Patients 
with low CD4 cell count at enrolment were shown to be more likely to be lost to follow up 
(Amuron et al., 2009; Lawn et al., 2006; Yiannoutsos et al., 2008). Other studies also 
indicated that low CD4 cell count was associated with high likelihood of mortality and 
decreased survival amongst patients (Barth et al., 2008; Lawn et al., 2006; Nachega et al., 
2006; Stringer et al., 2006). Additionally, in correlating CD4 cell count and likelihood of 
mortality, results indicated that the lower the CD4 cell count the higher the likelihood of 
death (Barth et al., 2008). Contrasting results were recorded by  Lebouche and others in their 
review of a clinical cohort of patients enrolled in an urban clinic in France indicated that 
patients who had a CD 4 cell count above 350 were more likely to be lost to follow up 
(Lebouche et al., 2006). 
2.2.7 Size and structure of the HIV care and treatment program 
Size of the ART program in terms of patient load and the level of patient tracing have also 
been shown to influence outcomes. Larger HIV care and treatment programs with high 
patient loads were less likely to trace patients lost to follow up resulting in high proportions 
of patients lost to follow up (Brinkhoft et al., 2008). HIV care and treatment programs with 
active follow up systems had lower lost to follow up rate (12%) with a median loss to follow 
up time of 5.8 months compared to 19% of patients lost to follow up in HIV care and 
treatment programs with passive follow up system with a median lost to follow up time of 3.4 
months (Brainstein et al., 2006). The level of health facility also influences patient outcomes 
as shown by a study in Malawi indicating that the rates of loss to follow up were far much 
higher in hospitals compared to that of health centres due to geographical access (Massaquoi 
et al., 2009). 
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2.2.8 Cost of care and treatment 
Cost has been shown to be an influence continuity of treatment amongst PLHIV and 
adherence to ART. HIV care and treatment programs that required partial or full payment for 
services had lower chances of retaining patients compared to those providing services for free 
in most cases (Rosen, Fox and Gill, 2007; Laurent et al., 2005; Mills et al., 2006). However a 
study of 15 treatment HIV care and treatment programs in Africa, Asia, and south America 
showed that free-for-service program was associated with increased probability of no follow 
up and death (Brinkhoft et al., 2008). 
2.2.9 Other factors 
Other factors contributing to loss to follow up and lack of adherence include lack of 
disclosure for fear of being stigmatized; patients movement out of catchment area and 
problems with transportation access; distance to the clinic related to the inconvenience of 
travel and transfer to another ART programme (Brinkhoft et al., 2008; Mills et al., 2006; 
Roura et al., 2009; Severe et al., 2005; Wools-Kalaustian et al., 2006). In a Gambia study, a 
significant 40% of patients were lost to follow up due to lack of disclosure of their HIV status 
to their family member of a friend before ART initiation (Togun et al., 2011). Underlying 
causes to drop out include premature death, competing causes of disease, alcohol or 
substance abuse, poverty and high mobility (Unge et al., 2009). 
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CHAPTER THREE 
METHODOLOGY  
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3.1 Study design 
This was a retrospective cohort study based on a retrospective review of patient clinical care 
and treatment data in NNPGH from January 2003 to December 2008. The study design was 
selected based on its strengths that include ability to determine cause of the problem - which 
in this study is loss to follow-up (LTFU); enable longitudinal follow up of patients; ability to 
estimate incidence and risk of an event which in this study is LTFU and allows for accurate 
measurement of exposure variables.  
3.2 Study population 
This study was set within A Retrospective Clinical Record Review: Nyanza Provincial 
General Hospital HIV Comprehensive Care Clinic: 2003 – 2008 study which was a 
retrospective study to review NNPGH program data and determine outcomes of adults and 
children enrolled in NNPGH between January 2003 and December 2008.  In this study, data 
of adult patients (15 years and above) enrolled between 2003 and 2008 was reviewed to 
determine LTFU amongst patients on care and ART.  
3.3 Inclusion and exclusion criteria 
Inclusion criteria: - To be included in this study, patients must have been enrolled in 
NNPGH CCC between 8
th
 January 2003 and 30
th
 September 2008; been older than 14 years 
of age at enrollment and have complete records.  
Exclusion criteria: - All patients that have been discontinued due to death or transfer out to 
other facilities were excluded from this study.  
3.4 Sampling 
Data used for this study were from the intake, enrollment and follow up databases which 
were for the same patients. A total of 9100 records were in the intake database and 9298 in 
the enrollment database. The intake and enrollment databases were merged into one database 
and only 6108 (3190 records were excluded from analysis due to missing intake information 
for 198 records and 2,992 records did not successfully link) which represented 78% of all 
patients were successfully linked. An additional 1,368 records were excluded from analysis 
due to missing key variables of analysis such as age, WHO clinical staging, marital status, 
employment status and type of treatment. A total of 4740 records were finally included in the 
analysis and successfully linked to the follow up database as indicated in figure 3.1 below. 
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Figure 3.1: Flow chart showing the records that were included into the study 
 
3.5 Data collection 
Data for this study was collected as part of routine patient care and treatment by health care 
providers who as part of clinical care completed standardized intake, enrolment, follow-up 
and discontinuation forms among others designed using Teleform
®
 version 10.0 Software.  
Information from the intake form provided social and demographic information such as age, 
gender, marital status, employment and level of education while enrolment and follow-up 
forms provided clinical information such CD4 level, WHO clinical staging and type of 
treatment the patient was on at baseline and at each follow-up visits respectively. These 
Enrollment + Intake 
database  
6108 of records 
successfully linked 
Unlinked records excluded 
3190 (198 with no intake 
information available and 
2,992 which did not link) 
were excluded 
Enrollment and intake database 
combined + follow-up database 
linked. 4,740 records included in 
final dataset for analysis. 
Records missing key 
information (analysis 
variables – Missing WHO 
and other variables); 
pediatrics excluded; 
patients discontinued; 
duplicate records. 
1,368 records excluded 
Intake database 
9100 of records 
Enrollment 
database 
9298 of records 
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forms once filled were then scanned into a password protected computer, verified, cleaned 
and finally stored into access based database.  The data sheet shown in the appendix I 
indicate the variables of interest abstracted from the electronic medical database to create 
dataset for analyses.  This database was then cleaned and the final variables picked for 
analysis. 
3.6 Validity and Reliability 
Automation of data entry through scanning of forms eliminated the need for manual data 
entry and as a result minimizing errors. Information bias was minimized by using a designed 
standard data tool for data extraction to ensure that similar information was extracted from 
the database for all records included in the analysis. I additionally relied on accurate record 
keeping using the electronic database. Integrity of data was ensured through data cleaning by 
checking for outliers and errors, eliminating duplicates and identifying and filling in missing 
data that was abstracted by trained data abstractors.   
 
Selection bias was minimized by providing all patients who were enrolled within the study 
period with equal opportunity of being included in the study and those excluded were due to 
incomplete records. Lastly, confounding was minimized by ensuring that possible 
confounding factors such as age, employment, marital status, treatment group, education and 
gender were included in the multivariate analysis to deal with interaction of one variable on 
another that may have otherwise resulted in a wrong conclusion on the effect of the variable 
on the outcome variable, loss to follow-up. 
 
3.7 Generalizability 
Findings from this study are therefore generalizable to the general adult population accessing 
HIV care and treatment in NNPGH CCC. 
 
3.8 Data analysis 
Data analysis was done using statistical analysis software (SAS) for windows version 9.2 
(SAS Institute, Cary, North Carolina, USA) and STATA version 10 (STATA Corp LP). 
Additionally, Microsoft office Excel 2007 was used in creating graphs. Loss to follow up was 
calculated by getting the difference in terms of days between the date the patient was last 
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seen in the clinic and the study censor date i.e. 31/12/2008. The difference was then 
dichotomized into equal or less than 90 days and more than 90 days. A patient was 
considered to be lost to follow up if he/she was absent from the clinic for a duration of more 
than 90 days, otherwise the patient was active as indicated in the MOH 257 Comprehensive 
Care Clinic Patient Card (Ministry of Health, 2007). 
 
To describe the baseline demographic characteristics of adult patients, frequencies and 
proportions of patient characteristics such as age, gender, education, employment, marital 
status, baseline CD4 cell count, clinical status (WHO clinical stage), type of treatment (either 
care or ART) and HIV status disclosure were done. Median was also computed for 
continuous variables like age because median is not much affected when variables are not 
normally distributed. Additionally, trends of patients at enrollment over the years (2003 – 
2008) were also analyzed by clinical status (WHO stage), gender, age and baseline CD4.  
Rates of loss to follow up of HIV infected adults, incidence and prevalence of loss to follow 
up were calculated by year, period of follow up, gender and clinical WHO staging. The 
incidence of loss to follow up was also be calculated at month 6, 12, 24, 36, 48 and 60 of 
follow up by year of enrollment and by period of treatment looking at type of treatment (Care 
or ART) at time of loss to follow up. 
To determine factors associated with loss to follow up, relative risk were calculated to 
explore the risks associated with loss to follow-up across different categories in each 
variable; Cox proportional hazard model was used to explore the association between various 
risk factors and loss to follow up. Hazard ratios and 95% confidence intervals were calculated 
to select the variables to be included in the final model. Associations (hazard ratio) and test of 
significance (Chi-square) were done. Cox proportion hazards model was done and all the 
presumed risk factors found to have p values of <0.25 from the bivariate analysis were then 
included in the multivariate analysis. The cut off p value of <0.25 was chosen based on the 
works of Bendel and Afifi (Bendel and Afifi, 1977) and Mickey and Greenland (Mickey and 
Greenland, 1989) which showed that this cut off point allows for the inclusion of all 
important variables even though it also has the disadvantage of including variables with 
questionable importance (Hosmer and Lemeshow, 2000). 
Risk factors analyzed included age, gender, level of education, employment, marital status, 
baseline CD4 cell count counts dichotomized into two groups (less than or equals 250l3 and 
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above 250l3), clinical status (WHO clinical stage) and HIV status disclosure. bivariate 
analyses of the presumed risk factors (age, gender, education, employment, marital status,  
baseline CD4 cell count, clinical status (WHO clinical stage), type of treatment and HIV 
status disclosure) and patient status (active versus lost to follow up) were done. Kaplan Meier 
survival curves were drawn for variables that change with time. 
3.9. Ethical considerations  
Human Subjects: The main study SSC No. 1525 from which data for this study was abstracted 
had been approved by the Kenya Medical Research (KEMRI) Ethical Review Committee (ERC) 
and US Centers for Disease Control and Prevention (CDC) Institutional review Board (IRB). 
This study proposal was submitted and received ethical clearance by the University of the 
Western Cape.  
 
Study Procedures & Risks: Data used in patient cohort reporting routinely collected to support 
medical services. Chances of inadvertent release of patient information were very remote because 
identifiers such as patient names were not in the electronic database. Additionally, patient-level 
information such as patient CCC identification number were stripped of personal identifiers and 
coded with a unique, database-specific number.  
 
Benefits: No direct benefit was gained by the patients but the results will help improve care and 
treatment for future clients at the CCC. 
 
Informed Consent:  Informed consent was not sought to review the data that had already been 
collected for the following reasons: Patients were not put at risk by this study because data had 
already been collected and entered into a database. The data analysis process required no contact 
with the patients and patients continued to receive care and treatment services in accordance with 
the standards of care in Kenya regardless of this study or its outcomes; rights of patients was not 
adversely affected; the information being analyzed during this study had already been collected 
and  Seeking patient’s informed consent before reviewing the data was not done because some 
patients included in the database may have already defaulted during and could not be traced. 
However, permission of the hospital to use the data was sought. 
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Confidentiality: Access to the database used in this study was limited to authorized project staff; 
the database remained in a secured location and in a password protected computer at 
KEMRI/CDC and no individual patient(s) will be identified when the results of this study are 
presented. All results will be reported in an aggregate form.  
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CHAPTER FOUR  
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4.1. Patient enrollment at baseline 
4.1.1 Patient enrollment by year 
The number of patients enrolled slightly increased from 1108 in 2003 to 1447 in 2004 
followed by a slight reduction in 2005; sharp decline to 248 in 2006; slight decline to 75 in 
2007 and then a sharp increase to 516 in 2008. 
 
 
Figure 4.1: Patient enrollment by year 
 
4.1.2 Patient enrollment by age group 
Enrollment of patients in 15-30 and 31-40 age groups were high in the first three years, and 
then declined in the following two years from 526 and 486 to 104 and 89 respectively. The 
>40 years age group had a decline from the second to fifth year from 414 to 9. Enrollment in 
all age groups had a sharp increase in 2008. 
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Figure 4.2 – Patient enrollment by age group and year 
 
4.1.3 Patient enrollment by WHO clinical stage  
Enrollment of patients in WHO clinical stage 1 and 2 increased steadily from 2003 to 2005, 
dropped sharply between 2005 and 2006; stabilized between 2006 and 2007; and finally 
sharply increased between 2007 and 2008. Enrollment of patients in WHO stage 3 and 4 
were initially very high over the first 3 years, then declined dramatically from 191 and 268 
to 16 and 13 respectively over the next 2 years. There was however a sharp increase in 
enrollments across all WHO clinical stages in the last year. 
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Figure 4.3 – Patient enrollment by WHO clinical stage and year 
 
4.1.4 Patient enrollment by type of treatment 
Enrollment of patients on ART were consistent over the period; whereas enrollment of 
patients on care only were initially very high over the first 3 years, then declined  
dramatically from 1273 to 69 over the next 2 years. There was however a sharp increase in 
the last year. 
 
Figure 4.4 – Patient enrollment by type of treatment and year 
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4.2. Baseline Socio-demographic and Clinical Characteristics 
 
 The median age of patients was 33 (IQR 27 - 41) years, 35.6% (1691/4740) were in the 31-
40 years age category, 25.2% (1195/4740) had no education, 50.1% (2377/4740) were single, 
and 42.2% (2000/4740) had employment. Only 1,547 (32.6%) records that had documented 
baseline CD4 results were included in the analysis for baseline CD4 patient characteristic 
(Refer to appendix 2). Of the total 4,740 patients 65% were female. Males were slightly older 
with the median age of 36 years compared to females who had a median age of 32 (15-80) 
years. The difference between males and females was significant across age groups (p 
<.0001). Most females (46.5%) were in the 15-30 age groups while males (40.1%) were in 
the 31-40 years age group. Most females (47.7%) had primary education while males (53.7%) 
had secondary education. Majority of females (64.9%) were unemployed compared to males 
(44.9%). Most males (60.3%) had disclosed their HIV status compared to 56.3% of females. 
The proportion of males who enrolled with advanced HIV status (WHO stage 4) was higher 
than that in females. There was no difference between males and females in the highest level 
of education attained, marital status and WHO clinical staging. 
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Table 4.1 - Baseline Socio-Demographic and Clinical Characteristics of patients 
enrolled in NNPGH CCC, 2003-2008 (N=4740) 
 
Characteristic  Female (%) Male (%)  p-value 
 
Enrolled patients 
 
3064 (64.6) 
 
1676 (35.4) 
  
Median age (IQR) in years 32 (26-39) 36 (30-44) <.0001 
Age in years at enrolment     <.0001 
  > 40 621 (20.3) 574 (34.3)   
  31-40 1019 (33.3) 672 (40.1)   
  15-30 1424 (46.5) 430 (25.7)   
Highest level of education     <.0001 
  None 189 (6.2) 47 (2.8)   
  Primary 1462 (47.7) 605 (36.1)   
  Secondary 1297 (42.3) 900 (53.7)   
  Post-secondary 116 (3.8) 124 (5.1)   
Treatment group     0.249 
  Care 2882 (94.1) 1590 (94.9)   
  ART 182 (5.9) 86 (5.1)   
Marital status     <.0001 
  Married 1232 (40.2) 1145 (68.3)   
  Single 602 (19.7) 262 (15.6)   
  Widowed/Divorced/Separated 1230 (40.1) 269 (16.1)   
Disclosed HIV status     0.007 
  Disclosed  1725 (56.3) 1011 (60.3)   
  No disclosure 1339 (43.7) 665 (39.7)   
Employment status     <.0001 
  Employed  1076 (35.1) 924 (55.1)   
  Unemployed  1988 (64.9) 752 (44.9)  
WHO Clinical Staging     <.0001 
1 547 (17.9) 189 (11.3)   
2 505 (16.5) 258 (15.4)   
3 1740 (56.8) 1006 (60.0)   
4 272 (8.9) 223 (13.3)   
Baseline CD4     0.987 
≤ 250 cells/l3 544 (53.7) 287 (53.8)   
> 250 cells/l3 469 (46.3) 247 (46.3)   
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4.3 Loss to follow-up of enrolled patients 
4.3.1 - Risk of loss to follow up of enrolled patients in NNPGH CCC 
The relative risk (RR) of loss to follow-up (LTFU) in the 15-30 years age group was 1.6 
(95%CI=0.89-1.19) times more than that in the >40 years age group. Patients who had no 
education, primary and secondary education were 2.9 (95%CI=1.88-4.44), 2.6(95%CI=1.94-
3.43) and 1.8 (95%CI=1.39-2.43) times respectively more like to be LTFU compared to those 
who had post-secondary education. Those in the ART group (RR=0.5, 95%CI=0.37-0.62) 
were less likely to be lost to follow up compared to Care group. Patients who had not 
disclosed their HIV status were 1.5 (95%CI=1.33-1.77) times more likely to be LTFU 
compared to those who had disclosed their HIV status. Only patients in WHO stage 4 
(RR=1.8, 95%CI=1.33-2.44) had a significant LTFU compared to those in WHO stage 1 
while those in WHO stage 2  and 3 were not significant. The differences in the rates of LTFU 
in the gender, marital status, employment status and baseline CD4 were not significant. 
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Table 4.2 - Risk of loss to follow up of enrolled patients in NNPGH CCC, 2003-2008 
(N=4740)  
 
Patient characteristic patients 
enrolled 
patients 
LTFU 
RR (95% CI) 
Gender     
Female 3064 2382 (77.7) ref 
Male 1676 1312 (78.3) 1.0 (0.89-1.19 
Age-group at enrolment      
  > 40 1195 882 (73.8) ref 
  31-40 1691 1301 (76.9) 1.2 (1.00-1.41) 
  15-30 1854 1511 (81.5) 1.6 (1.31-1.86) 
Highest level of education     
  None 236 196 (83.1) 2.9 (1.88-4.44) 
  Primary 2067 1683 (81.4) 2.6 (1.94-3.43) 
  Secondary 2197 1664 (75.7) 1.8 (1.39-2.43) 
  Post-secondary 240 151 (62.9) ref 
Treatment group     
  Care 4472 3523 (78.8) ref 
  ART 268 171 (63.8) 0.5 (0.37-0.62) 
Marital status     
  Married 2377 1827 (76.9) 0.9 (0.73-1.07) 
  Single 864 682 (78.9) ref 
  
Widowed/Divorced/Separated 
1499 1185 (79.1) 1.0 (0.82-1.24) 
Disclosed HIV status     
  Disclosed  2736 2049 (74.9) ref 
  Not disclosed 2004 1645 (82.1) 1.5 (1.33-1.77) 
Employment status     
  Employed  2000 1532 (76.6) 0.9 (0.76-1.01) 
  Unemployed  2740 2162 (78.9) ref 
WHO Clinical Staging     
1 736 561 (76.2) ref 
2 763 595 (78.0) 1.1 (0.87-1.41) 
3 2746 2116 (77.1) 1.0 (0.87-1.27) 
4 495 422 (85.3) 1.8 (0.76-1.24) 
Baseline CD4     
≤ 250 cells/l3 831 658 (79.2) ref 
> 250 cells/l3 716 563 (78.6) 1.0 (0.76-1.24) 
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4.3.2 Proportion of enrolled patients lost to follow up of at different time points in 
NNPGH CCC, 2003-2008 (N=3694)  
 
The proportion  of patients enrolled into care and LTFU was higher that those on ART in the 
in the 0-6 (12.5%), 7-12 (35.0%), 13-24 (2.0%) and 37-48 (9.2%) months after enrollment. 
There were however period where loss to follow-up in the ART group was higher than in the 
Care group was 12.5% higher than those on ART. This included 25-36 (7.9%), 49-60 )19.3% 
and 61-72 (12.0%)  months after enrollment.  
 
 
Figure 4.5 – Proportion of patients LTFU at different time points (months of follow-up) 
and treatment groups 
 
4.3.3. Rates of loss to follow up by year of enrollment of enrolled patients in NNPGH 
CCC  
The proportion of patients on both care and ART LTFU reduced over the years with 2003 
having the highest and 2008 the lowest. Rates of LTFU were however higher in the care 
group compared to ART group. Rates of LTFU were comparable in both groups in 2007 
though different in 2008 where the loss to follow up in the care group was much higher at 
46.6% of enrolled patients compared to that in the ART group at 18.8%. 
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Figure 4.6 – Rates of LTFU by year of enrollment 
 
4.3.4 Rates of loss to follow up of enrolled patients by gender in NNPGH CCC 
 
The difference in proportion of males and females enrolled into care and ART had minimal 
differences ranging from 0 – 1.3%. Rates were initially low though increased sharply in the 
following one year from 14.3% for males and 13% for females to 29% and 29.5% 
respectively, stabilized in 2005 followed by a sharp declined over the following 2 years from 
28.8% and 30.3% to 4.8% and 5 % respectively and finally a sharp increase in 2008. 
 
 
Figure 4.7 – Rates of LTFU of enrolled patients by gender and year 
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4.3.5 Rates of loss to follow up of enrolled patients by age in NNPGH CCC 
 
The proportions of patients LTFU in the 15-30 years and 31-40 years age groups over the 
years was minimal. The >40 years age group compared to  15-30 years and 31-40 years age 
groups was higher in 2004 compared to 2003 followed by a sharp decline in 2005 while 
trends were similar in all age groups over the last 3 years. 
 
 
Figure 4.8 – Rates of LTFU by age and year 
 
4.3.6 Rates of loss to follow up of enrolled patients by WHO stage in NNPGH CCC 
  
The rates of LTFU were high in 2004 across all WHO stages. There was however a 
difference in the next 1 year where rates for patients in WHO stage 1 and 3 stabilized while 
that in WHO stage 4 had a sharp decline and that of WHO stage 2 continued to increase. All 
WHO stages had a sharp decline in the following two years and finally a sharp increase in 
2008. Loss to follow up was highest in the WHO stage 4 in 2003 (20.9%) and in 2004 
(31.8%), in WHO stage 2 in 2005 (34.8%) and 2006 (8.7%), in WHO stage 3 (5.2%) and in 
WHO stage 1 in 2008 (18%). 
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Figure 4.9 – Rates of LTFU of enrolled patients by WHO clinical staging and  year  
 
4.4 Factors associated with loss to follow up  
 
The third objective of this study is to determine the factors which at enrolment are predictive 
of loss to follow up. 
 
4.4.1 Risk of loss to follow up 
Bivariate Hazard Ratio 
The risk of LTFU amongst patients with primary (HR=0.76, 95%CI=0.63-0.91) and 
secondary education (HR=0.67, 95%CI=0.52-0.87) were significantly lower compared to 
tertiary education.  Patients who had no education (HR= 0.83, 95%CI= 0.76-1.11) had risk of 
LTFU that was not significantly different to that of patients with tertiary education. 
  
Hazards of patients who had not disclosed their HIV status (HR=1.10, 95%CI=1.0-1.18) 
higher than in those who disclosed their HIV status. As for employment status, hazards of 
patients who had no employment (HR=1.20, 95%CI=1.11-1.31) were higher than those who 
were employed. Hazards of patients who had WHO clinical stage 4 was 1.43 (95%CI=1.20-
1.69) higher than that of patients in WHO clinical stage 1 while those of patients in WHO 
clinical stage 2 (HR=1.05, 95%CI=0.90-1.22) and stage 3 (HR=1.03, 95%CI=0.91-1.17) had 
no significant difference. Hazards of LTFU in patients in 31-40 years and 15-30 years groups 
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were 1.12 (95%CI=1.01-1.24) and 1.36 (95%CI=1.22-1.51) higher than that of patients in the 
>40 years category.  
 
As for the type of treatment, the patients who were on ART at enrolment (HR=0.62, 
95%CI=0.51-0.76) were lower than that of patients in care. The hazards of patients who had a 
baseline CD4 >250 cells/l3 (HR=0.67, 95%CI=0.51-0.87) were lower compared to that in 
patients who had a baseline CD4 ≤250 cells/l3. On the other hand, the hazards of males 
(HR=1.01, 95%CI=0.93-1.10) compared to females and patients who were 
divorced/separated/widowed (HR=0.99, 95%CI=0.88-1.12) and married/cohabiting 
(HR=0.94, 95%CI=0.84-1.05) compared to those who were single had no stastically 
significant difference. 
 
Multivariate analysis 
All factors with P-value of <0.25 in the bivariate HR and gender with a p value >0.25 were 
included in the multivariate analysis. Gender was included because it is a demographic 
characteristic of importance to LTFU. Variables included were gender; 31-40 years age-
group; 15-30 years age-group; unemployment; WHO stage 4; primary and secondary 
education; no disclosure of HIV status and ART group. CD4 group was not included in the 
multivariate analysis due to the limited number of patients who had their baseline CD4 cell 
count records available in the database hence WHO clinical staging was used as a proxy to 
CD4 cells count in indicating level of disease progression.  
 
After adjusting for other variables, the hazards of males being LTFU were 1.12 
(95%CI=1.02-1.22) higher than that of females. Patients with Primary (AHR=0.73, 
95%CI=0.61-0.90) and secondary (AHR=0.69, 95%CI=0.53-0.91) level of education had 
lower hazards to LTFU than those with tertiary education while patients who had no 
education (AHR=0.92, 95% CI=0.76-1.11) had hazards that were not significantly different 
from that of patients with tertiary education after controlling for other factors. As for 
employment status, hazards (AHR=1.14, 95%CI=1.05-1.25) of patients who had no 
employment was higher than that those who were employed after controlling for other 
factors. Controlling for other factors, hazards of patients who had WHO clinical stage 4 was 
1.53 (CI=1.29-1.81) higher than that that of patients in WHO clinical stage 1 while those of 
patients in WHO clinical stage 2 (AHR=1.07, 95%CI=0.92-1.25) and 3 (AHR=1.05, 
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95%CI=0.93-1.20) had no significant difference. Controlling for other factors, the hazards of 
LTFU in patients in 31-40 years and 15-30 years groups were 1.15 (95%CI=1.03-1.28) and 
1.37 (95%CI=1.23-1.53) higher than that of patients in the >40 years category. As for the 
type of treatment the patient was on at enrollment, the hazards of patients on ART 
(AHR=0.64, 95%CI=0.52-0.78) were lower than that of patients in care after controlling for 
other factors. Controlling for other factors, the hazards of patients who had not disclosed their 
HIV status (AHR=1.05, 95% CI=0.97-1.14) were not significantly different to those who had 
disclosed their HIV status. 
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Table 4.3 – Factors associated with loss to follow up in NNPGH CCC, 2003 – 2008 
Characteristic  Multivariate 
HR (95% CI) AHR (95% CI)  
Gender      
  Female ref ref  
Male 1.01(0.93 - 1.10) 1.12 (1.02 – 1.22)  
Education level      
  None 0.98 (0.81 - 1.18) 0.92 (0.76 - 1.11)  
  Primary 0.76 (0.63 - 0.91) 0.73 (0.61 – 0.90)  
  Secondary 0.67 (0.52 - 0.87) 0.69 (0.53 – 0.91)  
Tertiary ref ref  
Marital status      
Single   ref ref  
  Married/Cohabiting 0.94 (0.84 - 1.05) -  
Divorced/Separated/Wido
wed 
0.99 (0.88 - 1.12) -  
Disclosed HIV status      
Disclosed ref ref  
Not disclosed 1.10 (1.0 - 1.18) 1.05 (0.97 – 1.14)  
Employment status      
  Employed ref ref  
  Unemployed 1.20 (1.11 - 1.31) 1.14 (1.05 – 1.25)  
WHO disease stage      
  Stage 1 ref ref  
  Stage 2 1.05 (0.90 - 1.22) 1.07 (0.92 – 1.25)  
  Stage 3 1.03 (0.91 - 1.17) 1.05 (0.93 – 1.20)  
  Stage 4 1.43 (1.20 - 1.69) 1.53 (1.29 – 1.81  
Age group      
  31-40 years 1.12 (1.01 - 1.24) 1.15 (1.03 – 1.28)  
  15-30 years 1.36 (1.22 - 1.51) 1.37 (1.23 – 1.53  
  > 40 years ref ref  
Treatment type      
  Care ref ref  
  ART 0.62 (0.51 - 0.76) 0.64 (0.52 – 0.78)  
Baseline CD4      
≤ 250 cells/l³ ref ref  
> 250 cells/l³ 0.67 (0.51 - 0.87) -  
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4.5 Kaplan-Meier survival analysis  
In this section, comparison of loss to follow up by treatment type, age group and WHO 
clinical staging through-out follow up period is presented. 
 
4.5.1 Loss to follow up by treatment type 
Patients on care had a faster loss to follow-up rate especially in the first 500 days of follow up 
and then the rate has steady decline. The drop out rate in the ART group but is higher after 
1500 days of follow up though still lower with better survival than that of care group. There 
was a significant difference in the survival rates for the two groups (p=<0.0001). 
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Figure 4.10 – Survival curve of patients in care and ART at enrollment 
 
 
 
 
 
 
 
 
 
 
Log Rank test P-value <0.0001 
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4.5.2 Loss to follow up by age group 
Patients in the 15-30 years age group were lost to follow-up at a faster rate and had lowest 
survival rates compared to 31-40 and > 40 years age groups while the > 40 years had the 
slowest rate of loss to follow up and highest survival rates and there was a significant 
difference between the groups (p=<0.0001). 
 
0
.0
0
0
.2
5
0
.5
0
0
.7
5
1
.0
0
P
ro
p
o
rt
io
n
 s
u
rv
iv
a
l
0 500 1000 1500 2000
time(days) to lost to follow up
agegroup = 15-30 years agegroup = 31-40 years
agegroup = > 40 years
Kaplan-Meier survival estimates, by age-group
 
Figure 4.11 – Survival curve of patients by age group at enrollment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Log Rank test P-value <0.0001 
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4.5.3 Loss to follow up by WHO stage 
Patients with WHO stage 4 were lost to follow-up at a higher rate than those in WHO 1, 2 
and 3 with least survival. On the other hand, Patients in WHO stage 1, 2 and 3 had similar 
dropout rates though patients in WHO stage 1 had highest survival rates compared to WHO 
stage 2 and 3 with similar survival. Log rank test showed that there was a significant 
difference in the different groups of WHO disease clinical staging. 
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Figure 4.12 – Survival curves of patients by WHO clinical staging 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Log Rank test P-value <0.0001 
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4.5.4 Loss to follow up by CD4 group 
The loss to follow-up rate are similar for both groups except at the end of follow up period 
where the ≤ 250 cells/l3 have better retention compared to the > 250 cell/l3 group. The 
survival rates for the two categories of baseline CD4 were the same. 
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Figure 4.13 – Survival curves of patients by CD4 count 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Log Rank test P-value 0.7785 
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CHAPTER FIVE 
DISCUSSION 
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5.1 Characteristics of patients at enrollment 
The median age of patients was 33(IQR 27 - 41) years and was consistent with most studies 
and HIV care and treatment programs in Sub Sahara Africa (Barth et al., 2008; Lawn et al., 
2006; Stringer et al., 2006; Brinkhoft et al., 2008). The result was however not consistent 
with studies in Kibera, Western Kenya program in and study in Uganda which had patients 
with a median age of more than 35 years (Kamya et al., 2007; Marston et al., 2007; Wools-
Kalaustian et al., 2006). 
 
Females were dominant (65%) amongst enrolled patients with similar results noted in most 
HIV care and treatment programs (Lawn et al., 2006; Amuron et al., 2009; Brinkhoft et al., 
2008; Kamya et al., 2007; Marston et al., 2007; Orrell et al., 2007; Stringer et al., 2006; 
Wools-Kalaustian et al., 2006). This was expected since the prevalence rate of HIV for 
females in the province is much higher than males (National AIDS and STI Control Program 
and Kenya Ministry of Health, 2009). The results were however inconsistent with findings in 
France which may could have been because the clinic in France was mainly male population 
(Lebouche et al., 2006) and Malawi (Makombe et al., 2008) HIV care and treatment 
programs where males were 75% and 78% respectively of patients enrolled. 
 
Of the total  number of the enrolled patients, (25%) of patients enrolled had no education and 
the proportion was much higher compared to cohorts in Kenya which had 8% (Wools-
Kalaustian et al., 2006) and 17% in Haiti (Severe et al., 2005) though was much lower 
compared to the South African cohort which had 51% with no education (Barth et al., 2008). 
The high proportions of patients with no education may be attributed to the pockets of 
informal settlements in the hospital’s catchment area. 
 
Patients in this study had a median CD4 cell count of 226 cells/l3. This was consistent with 
some HIV care and treatment programs that had median CD4 cell count of ≤250 cells/l3 
(Barth et al., 2008; Kamya et al., 2007; Lawn et al., 2006; Lawn et al., 2005; Orrell et al., 
2007; Wools-Kalaustian et al., 2006; Brinkhoft et al., 2008; Marston et al., 2007; Stringer et 
al., 2006). The proportion (68%) of patients enrolled in this study had WHO clinical stage 3 
and 4 was consistent with findings of some with less than 70% of patients in WHO clinical 
stage 3 and 4 at enrollment (Amuron et al., 2009; Brinkhoft et al., 2008; Wools-Kalaustian et 
al., 2006). However, the results were not consistent with some HIV care and treatment 
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programs which showed that more than 70% of patients initiating ART in Sub Sahara Africa 
were in WHO clinical stage 3 and 4 at enrollment (Barth et al., 2008; Kamya et al., 2007; 
Lawn et al., 2006; Lawn et al., 2005; Makombe et al., 2008; Marston et al., 2007; Stringer et 
al., 2006). Most of the patients enrolled in the study at advanced stage of the disease could be 
attributed to attempts to seek care from other alternative methods like traditional medicine, 
religion (holy water) or belief on other issues like breaking of taboos as source of the ailment 
and belief in witch craft. 
 
Proportion of patients (42%) enrolled in this study had employment and was higher compared 
to 23.9% in South Africa (Barth et al., 2008) and 30.5% in the western Kenya program 
(Wools-Kalaustian et al., 2006). Of the patients enrolled, 50% were married at enrollment. 
This was consistent to the cohort in South Africa (Barth et al., 2008) though not consistent 
with to results of the Western Kenya cohort which was 64% (Wools-Kalaustian et al., 2006). 
5.2 Overall loss to follow-up rates 
The overall LTFU for both patients on care and ART from 2003 to 2008 was 78%. LTFU at 
12 months was 74% (26% retention) while that of patients on care and ART were 76% (24% 
retention) and 41% (57% retention). At 24 months of follow up, rates of LTFU was 96% (4% 
retention) for both care and ART, 97% (3% retention) for patients on care and 94% (6% 
retention) for patients on ART. At 12 months of follow-up, LTFU rate of 41% (59% 
retention) was not consistent with results of 25% (retention 75%) in Sub-Sahara Africa HIV 
care and treatment programs (WHO, 2009). This could be attributed to patients choosing to 
self-transfer to new sites that were established in other districts after NNPGH. Similarly at 24 
months of follow-up, 94% LTFU rates of patients on ART was not consistent with 33% 
shown in Sub-Sahara Africa (WHO, 2009). Generally, rates of LTFU amongst patients on 
ART were 41% and 94% at 12 and 24 months of follow-up which was inconsistent with 3%-
29% in most HIV care and treatment programs in Sub-Sahara Africa (Barth et al., 2008; 
Bekker et al., 2006; Dalal et al., 2008; Laurent et al., 2005; Lawn et al., 2006; Makombe et 
al., 2008; Orrell et al., 2007; Severe et al., 2005; Sow et al., 2007; Wools-Kalaustian et al., 
2006; Yu et al., 2007). The high rates of LTFU could be attributed to limited options of HIV 
clinics in the initial years of the program and patients travelled long distances for services 
hence may have been unable to keep clinic appointments. The second attributable reason 
could have been due to rapid decentralization (establishment of new clinics) leading to 
patients who had initially enrolled in the program opted to be enrolled in other clinics near 
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their homes without informing NNPGH program. The post-election violence that occurred in 
Kenya with Kisumu amongst hard hit areas may have also contributed to LTFU in 2007 and 
2008. 
 
5.3 Factors contributing to loss to follow up 
Males were more likely to be LTFU (AHR=1.12, P=0.018) and was consistent with results in 
France and Sub-Sahara Africa (Amuron et al., 2009; Lebouche et al., 2006; Wools-
Kalaustian et al., 2006). These results were not consistent with those of the study in Malawi 
showed that females were more likely to be LTFU in the peripheral hospitals more than in the 
central hospital. (Yu et al., 2007). This may have been due to the reason that the women in 
the peripheral hospitals which may have been in the rural areas were very busy with farming 
activities. Additionally, the decision on whether women continued with care may have been 
made by other persons such as spouses.   
 
Patients who had primary education were less likely to be LTFU compared to those who had 
post-secondary education (AHR=0.73, P=0.002). This was also evident in secondary level of 
education where those who had secondary level of education were less likely to be LTFU 
compared to those who had post-secondary education (AHR=0.69, P=0.008). There was 
however no significant difference between patients who had no education (AHR=0.98, 
P=0.379) and those who had post-secondary education.   
 
The difference between patients who had disclosed their HIV status and those who had not 
disclosed was not significant (AHR=1.05, P=0.244). This was not consistent with a review 
done by Mills and others indicated that lack of disclosing HIV status was associated with 
dropping out of treatment (Mills et al., 2006). Though the difference was not significant, lack 
of disclosure for fear of discrimination could have also contributed to LTFU in this study. 
 
Unemployed (AHR=1.14, P=0.003) patients were more likely to be LTFU. This was 
consistent with results found in Kibera (Unge et al., 2009) and France (Lebouche et al., 2006) 
though not consistent with those in Yaunde Cameroon which showed no association 
(Rougemont et al., 2009). This could be inability of the patients to afford transportation cost 
to attend clinic for follow up as required, poor nutrition status and not able to afford 
prescription drugs leading to mortality. 
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Patients with advanced HIV disease (WHO clinical stage 4) were more likely to be LTFU 
(AHR=1.15, P=<0.0001) compared to those in WHO clinical stage 1. These findings are 
similar to those recorded in other studies  (Rougemont et al., 2009; Stringer et al., 2006; 
Yiannoutsos et al., 2008; Yu et al., 2007). There was no significant difference when patients 
in WHO stage 2 (AHR=1.07, P=0.372) and WHO stage 3 (AHR=1.05, P=0.402). Finding of 
this study were however contrary to those by Brinkhoft and others and Lawn and others 
which indicated that advanced HIV clinical disease was not associated with loss to follow-up 
(Brinkhoft et al., 2008; Lawn et al., 2006). This could be attributed to the reason that patients 
with advance disease are more likely to remain active in treatment as they really need it or 
because they have seen the benefit of treatment. 
 
Younger patients in the age-group15-30 years were more likely to be LTFU compared to the 
older age-group and this showed significant results (AHR=1.30, P=<0.0001) and those 
patients in the age-group 31-40 years were more likely to be LTFU compared to older (> 40 
years) patients (AHR=1.15, P=0.011). These findings were consistent with studies in Migori 
(Karcher et al., 2007) and France (Lebouche et al., 2006) though not consistent with a study 
done by Brinkhoft and others in 2008 in Yaunde Cameroon which showed that older patients 
(>50 years) were more likely not to return for follow-up. The younger age-group could be 
highly migratory to other urban centres for employment or studies which may have resulted 
in self transfers to other treatment clinic closer to their new residences. The older population 
may have had less frequent movements as they may not have been actively searching for 
employment or going to colleges for studies. 
 
Patients who were on ART (AHR=1.37, P=<0.0001) at enrollment were less likely to be 
LTFU compared to those who were on care although studies reviewed did not compare the 
two groups. The patients who are enrolled in ART may have already known the benefits of 
adherence through knowledge on HIV treatment and dangers of non-adherence the drug 
gained from adherence counselling classes.  
 
It was worth noting that a patient may have been LTFU at NNPGH but accessing care and 
treatment in other facilities that were being established, therefore LTFU in this study may not 
mean that a patient has stopped treatment or has completely defaulted the HIV care and 
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treatment services. The true LTFU were the ones that died and the facility has a proper 
documentation on the same. 
 
5.4 Limitations 
Since the study did not include variables like user fee (amount of money a patient was 
required to pay for services); holy water, religious factors, distance from the hospital; amount 
of time spent to travel to hospital; accessibility of the hospital; alcohol and substance abuse; 
place of work in relation to the hospital, type of work in relation to travel requirements, it was 
not possible to test the effects that this variable had on LTFU. Data was also incomplete for 
some patients and there could have been errors during data entry by the clinicians and during 
data verification process. 
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CHAPTER SIX 
CONCLUSIONS AND RECOMMENDATIONS 
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6.1 Conclusions 
 
The overall LTFU was 78% over the six years of patients follow up. Rates of loss to follow 
up of patients on care and ART at 12 months of follow up was 76% and 41% respectively 
while LTFU at 24 months of follow up was 97% for patients on care and 94% for patients on 
ART. This presents retention of patients in the program as a problem that need to be 
addressed more so for patients on care. 
 
Several records were excluded from analysis due to incompleteness and failure to link patient 
information in the different databases which may have been due to wrong data entry or 
improper filing of patient forms and could lead to lack of continuity of patient care. This 
presents documentation as a problem that needs to be addressed. 
 
Factors including male gender, unemployment, advance HIV disease, younger patients, 
patients on care were significantly associated with LTFU hence present as a problem that 
need to be addressed. 
 
6.2 Recommendations 
Based on the determination of rates of loss to follow up and factors associated with loss to 
follow up amongst HIV and AIDS patients in care and treatment in Kisumu, Kenya; the 
following recommendations are made to the program: 
1. More attention is needed in developing retention strategies for patients with much 
focus on patients on care and those who have been follow-up for prolonged period of 
time. 
2. Data quality need to be strengthened by ensuring completeness of information at point 
of entry and proper filing practices put in place including regular cleaning of data in 
the electronic databases to facilitate accurate reporting.  
3. Need to develop tailored HIV care and treatment programs with much focus on 
identifying and addressing problems predisposing males, unemployed patients, and 
enrollment of patients with HIV disease at an advanced stage, younger patients and 
patients on care to loss to follow-up. This will contribute in reducing LTFU with 
improved treatment outcomes. 
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Appendices 
Appendix 1- PATIENT DATA TOOL 
        
 Form #                                       
 
Patient information at enrollment 
 
 
Patient CCC No     -                                                         
 
Enrollment date              /               /  
 
Date of Birth                /               / 
 
 
Patient age at enrollment                 years  
 
Patient’s sex  O Male O Female 
 
Marital status O Single O Married monogamous  
O Married polygamous O Divorced/Separated O Widowed     
 
 
No. of years of schooling 
 
 
Employment status  O Employed outside home O Unemployed                        
 
 
Has the patient disclosed their HIV status to anyone? O Yes O No 
 If yes, specify 
 O Spouse O Other family member O Friends  
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O other specify 
 
 
WHO stage at enrollment    O Stage 1     O Stage 2     O Stage 3     O Stage 4     O Missing 
 
 
WHO stage when last seen in CCC   
O Stage 1     O Stage 2     O Stage 3     O Stage 4      O Missing 
 
Type of care at time of data collection O CPT  O ARVs 
 
 
Duration on Care only or ART               months                     
 
 
Baseline CD4 count     
 
 
CD 4 when last seen in the clinic  
 
 
Date of ART initiation                /              /  
 
 
Date patient last seen in the clinic                 /              / 
 
 
Date of expected next clinic visit                  /              / 
 
 
What is the current status of patient outcome? 
O Defaulter  O Loss to follow-up  O Transfer out        O Death 
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Appendix 2: Baseline Socio-Demographic and clinical Characteristics of Patients 
enrolled in NNPGH CCC, 2003 – 2008 (N=4740) 
Characteristic  Frequency % 
Gender   
 Females 3064 65 
 Males 1676 35 
Age in years at enrolment   
  15-30 1854 25 
  31-40 1691 36 
  > 40 1195 39 
Highest level of education   
  None 236 5 
  Primary 2067 44 
  Secondary 2197 46 
  Post-secondary 240 5 
Treatment group   
  Care 4472 94 
  ART 268 6 
Marital status   
  Married 864 18 
  Single 2377 50 
  Widowed/Divorced/Separated 1499 32 
Disclosed HIV status   
  Disclosed  2376 58 
  No disclosure 2004 42 
Employment status   
  Employed  2000 42 
  Unemployed  240 58 
WHO Clinical Staging   
1 736 16 
2 763 16 
3 2746 58 
4 495 10 
Baseline CD4*   
≤ 250 cells/mm³ 831 18 
> 250 cells/mm³ 716 15 
*3193 records were missing 
 
 
 
 
 
